决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression.
我们的研究揭示了HSTCL发病机制中异质性和动态的肿瘤及微环境,并可能有助于未来识别HSTCL诊断和治疗的新靶点。
肝脾T细胞淋巴瘤(HSTCL)主要来源于γδ T细胞,是一种罕见但极具侵袭性的淋巴瘤,预后不良。在本研究中,我们构建了该罕见疾病的首个单细胞图谱,并阐明了疾病进展背后的分子发病机制。
我们对一名HSTCL患者化疗前后的活检样本进行了配对单细胞RNA测序和T细胞受体(TCR)测序。随后通过一系列生物信息学分析,我们研究了γδ HSTCS的基因表达谱及其肿瘤微环境(TME)。
我们通过一组在HSTCL中新鉴定的标志基因(AREG、PLEKHA5、VCAM1等)刻画了恶性γδ T细胞独特的基因表达特征。尽管恶性γδ T细胞由单一TCR克隆型扩增而来,但在疾病进展过程中它们演化为两种转录上不同的肿瘤亚型。Tumor_1亚型在治疗前样本中占优势,具有高度侵袭性表型。而Tumor_2具有相对温和的癌症标志特征,但表达与肿瘤生存信号和耐药相关的基因(IL32、TOX2、AIF1、AKAP12、CD38等),并最终在治疗后成为主要肿瘤亚型。我们进一步剖析了肿瘤微环境,发现了治疗过程中动态重塑的细胞间相互作用网络。治疗后肿瘤细胞与微环境的通讯减少。
PURPOSE: Hepatosplenic T-cell lymphoma (HSTCL), mostly derived from γδ T cells, is a rare but very aggressive lymphoma with poor outcomes. In this study, we generated the first single cell landscape for this rare disease and characterized the molecular pathogenesis underlying the disease progression. METHODS: We performed paired single cell RNA-seq and T cell receptor (TCR) sequencing on biopsies from a HSTCL patient pre- and post- chemotherapy treatments. Following by a series of bioinformatics analysis, we investigated the gene expression profile of γδ HSTCS as well as its tumor microenvironment (TME). RESULTS: We characterized the unique gene expressing signatures of malignant γδ T cells with a set of marker genes were newly identified in HSTCL (AREG, PLEKHA5, VCAM1 etc.). Although the malignant γδ T cells were expanded from a single TCR clonotype, they evolved into two transcriptionally distinct tumor subtypes during the disease progression. The Tumor_1 subtype was dominant in pre-treatment samples with highly aggressive phenotypes. While the Tumor_2 had relative mild cancer hallmark signatures but expressed genes associated with tumor survival signal and drug resistance (IL32, TOX2, AIF1, AKAP12, CD38 etc.), and eventually became the main tumor subtype post-treatment. We further dissected the tumor microenvironment and discovered the dynamically rewiring cell-cell interaction networks during the treatment. The tumor cells had reduced communications with the microenvironment post-treatment. CONCLUSIONS: Our study reveals heterogenous and dynamic tumor and microenvironment underlying pathogenesis of HSTCL and may contribute to identify novel targets for diagnosis and treatment of HSTCL in the future.
MEMBER ACCOUNT
登录成功会直接打开下一页。